Precision Medicine Stocks
Advanced therapeutic and diagnostic developers in this sector specialize in molecular-level interventions and high-resolution imaging to tailor medical treatments to individual genetic profiles. Revenue models center on proprietary platform technologies and specialized instrumentation used to identify specific biomarkers or execute robotic-assisted procedures with sub-millimeter accuracy.
As of Oct 23, 2026, Precision Medicine has 146 US-listed companies worth $844B combined. The median member moved +2.9% over the past week; GRAL led among the 25 largest at +12.5% and IR trailed at -5.5%.
Companies in Precision Medicine
- DE – Deere & Company, $174B
- ISRG – Intuitive Surgical Inc, $160B
- NTRA – Natera Inc, $57.9B
- IDXX – IDEXX Laboratories Inc, $44.6B
- ILMN – Illumina Inc, $40.7B
- RVMD – Revolution Medicines Inc, $40.2B
- MTD – Mettler-Toledo International Inc, $33.5B
- IR – Ingersoll Rand Inc, $28.8B
- GH – Guardant Health Inc, $21.9B
- CNH – CNH Industrial N.V., $18.6B
- NDSN – Nordson Corporation, $17.8B
- BBIO – BridgeBio Pharma Inc, $13.4B
- TEM – Tempus AI, Inc. Class A Common Stock, $12.3B
- TXG – 10X Genomics Inc, $9.8B
- CAI – Caris Life Sciences, Inc. Common Stock, $9B
- CYTK – Cytokinetics Inc, $8.5B
- AGCO – AGCO Corporation, $7.4B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- LNTH – Lantheus Holdings Inc, $6.5B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- GRAL – GRAIL, LLC, $5.7B
- COGT – Cogent Biosciences Inc, $5.5B
- MMED – MiniMed Group, Inc. Common Stock, $5.2B
- ERAS – Erasca Inc, $5.1B
- BLLN – BillionToOne, Inc. Class A Common Stock, $4.8B
- CRSP – Crispr Therapeutics AG, $4.8B
- TNGX – Tango Therapeutics Inc, $4.5B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- RLAY – Relay Therapeutics Inc, $4B
- TLX – Telix Pharmaceuticals Limited, $3.8B
- VCYT – Veracyte Inc, $3.7B
- CDNA – CareDx Inc, $3.6B
- IDYA – Ideaya Biosciences Inc, $3.5B
- CELC – Celcuity LLC, $3.2B
- KN – Knowles Cor, $3B
- DYN – Dyne Therapeutics Inc, $2.9B
- ELVN – Enliven Therapeutics Inc., $2.9B
- BEAM – Beam Therapeutics Inc, $2.5B
- PGEN – Precigen Inc, $2.3B
- WGS – GeneDx Holdings Corp., $2B
- ALMR – Alamar Biosciences, Inc. Common Stock, $2B
- SRPT – Sarepta Therapeutics Inc, $1.8B
- PSNL – Personalis Inc, $1.7B
- NBTX – Nanobiotix, $1.7B
- NTLA – Intellia Therapeutics Inc, $1.6B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- AAPG – Ascentage Pharma Group International, $1.4B
- FRNM – Freenome, Inc. Common stock, $1.4B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- KARD – Kardigan, Inc. Common Stock, $1.2B
- SNDX – Syndax Pharmaceuticals Inc, $1.2B
- CSTL – Castle Biosciences Inc, $1.1B
- IMTX – Immatics NV, $1B
- ANRO – Alto Neuroscience, Inc., $956M
- BRAI – Braiin Limited Common Stock, $956M
- KURA – Kura Oncology Inc, $944M
- ODTX – Odyssey Therapeutics, Inc. Common Stock, $871M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- SLDB – Solid Biosciences LLC, $737M
- FTH – Faeth Therapeutics, Inc., $733M
- NVCT – Nuvectis Pharma Inc, $716M
- FDMT – 4D Molecular Therapeutics Inc, $711M
- PRME – Prime Medicine, Inc. Common Stock, $707M
- SOPH – Sophia Genetics SA, $687M
- AURA – Aura Biosciences Inc, $678M
- SLN – Silence Therapeutics PLC, $613M
- FLGT – Fulgent Genetics Inc, $591M
- PACB – Pacific Biosciences of California, $572M
- MNPR – Monopar Therapeutics Inc, $498M
- YDES – YD Bio Ltd, $477M
- RGNX – Regenxbio Inc, $473M
- ARVN – Arvinas Inc, $472M
- OCS – Oculis Holding AG Ordinary shares, $461M
- EDIT – Editas Medicine Inc, $445M
- NGNE – Neurogene Inc, $431M
- NAUT – Nautilus Biotechnology Inc, $412M
- RCEL – Avita Medical Ltd, $404M
- MYGN – Myriad Genetics Inc, $396M
- CARL – Carlsmed, Inc., $390M
- SCTX – Scribe Therapeutics Inc. Common Stock, $380M
- PRE – Prenetics Global Ltd, $361M
- BDSX – Biodesix Inc, $279M
- CLPT – Clearpoint Neuro Inc, $277M
- BBOT – BridgeBio Oncology Therapeutics, Inc., $265M
- CATX – Perspective Therapeutics Inc., $259M
- PRLD – Prelude Therapeutics Inc, $258M
- ACIU – AC Immune Ltd, $256M
- CABA – Cabaletta Bio Inc, $251M
- BCYC – Bicycle Therapeutics Ltd, $245M
- LXEO – Lexeo Therapeutics, Inc. Common Stock, $217M
- TRDA – Entrada Therapeutics Inc, $209M
- RXST – Rxsight Inc, $203M
- STRO – Sutro Biopharma, $181M
- DTIL – Precision BioSciences Inc, $173M
- MOLN – Molecular Partners AG ADR, $165M
- BNR – Burning Rock Biotech Ltd, $158M
- KRRO – Korro Bio, Inc., $141M
- RNA – Atrium Therapeutics, Inc. Common Stock, $130M
- HURA – TuHURA Biosciences Inc, $117M
- SPRB – Spruce Biosciences, Inc. Common Stock, $116M
- SOTK – Sono-Tek Corp, $112M
- FHTX – Foghorn Therapeutics Inc, $110M
- IMDX – Insight Molecular Diagnostics Inc., $107M
- BDTX – Black Diamond Therapeutics Inc, $105M
- PMVP – Pmv Pharmaceuticals Inc, $105M
- OKUR – OnKure Therapeutics, Inc., $97.6M
- NMRA – Neumora Therapeutics, Inc., $89.4M
- TNYA – Tenaya Therapeutics Inc, $87.5M
- ACRV – Acrivon Therapeutics, Inc. Common Stock, $81.8M
- SERA – Sera Prognostics Inc, $80.5M
- IBIO – iBio, Inc. Common Stock, $72.3M
- CING – Cingulate Inc, $63.4M
- MDXH – MDxHealth SA, $63M
- XLO – Xilio Development Inc, $58.6M
- BOLD – Boundless Bio, Inc. Common Stock, $58.5M
- TPCS – TechPrecision Corporation Common stock, $54.6M
- RNXT – RenovoRx Inc, $52.4M
- CRBU – Caribou Biosciences Inc, $50.4M
- TVGN – Tevogen Bio Holdings Inc., $46M
- HOWL – Werewolf Therapeutics Inc, $45.2M
- PRPO – Precipio Inc, $38.9M
- MGX – Metagenomi, Inc. Common Stock, $37.8M
- ATNM – Actinium Pharmaceuticals Inc, $30.6M
- BCTX – Briacell Therapeutics Corp, $30.1M
- MLSS – Milestone Scientific, $29.6M
- ARAY – Accuray Incorporated, $18.6M
- RADX – Radiopharm Theranostics Limited American Depositary Shares, $15.8M
- BNGO – Bionano Genomics Inc, $14.4M
- ALLR – Allarity Therapeutics Inc, $13.9M
- CLRB – Cellectar Biosciences Inc, $13.1M
- CNSY – Cerenome, Inc., $12.9M
- ADIL – Adial Pharmaceuticals Inc, $12.2M
- ADVB – Advanced Biomed Inc. Common Stock, $10.5M
- LTRN – Lantern Pharma Inc, $9.6M
- AZTR – Azitra Inc, $7.9M
- SNTI – Senti Biosciences Inc, $7.1M
- VNRX – Volitionrx Ltd, $5.4M
- CDIO – Cardio Diagnostics Holdings Inc, $5.2M
- NIKI – Niki BioSolutions, Inc., $3.7M
- BGLC – BioNexus Gene Lab Corp Common stock, $3.6M
- ADTX – Aditxt Inc. , $3M
- BCAB – Bioatla Inc, $2.5M
- CALA – Calithera Biosciences Inc, $487
- TBIO – Telesis Bio Inc., $177